ストックスクリーナーアプリを入手
0.5909
0.57%
0.0109
Oragenics Inc (OGEN) 最新ニュース
Price to book forward of Oragenics Inc. – AMEX:OGEN - TradingView
Enterprise value to EBIT forward of Oragenics Inc. – AMEX:OGEN - TradingView
Enterprise value to revenue forward of Oragenics Inc. – AMEX:OGEN - TradingView
Oragenics Inc (OGEN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Oragenics Inc (OGEN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Oragenics, Inc. Actuals & Estimates (AMEX:OGEN) - TradingView
Oragenics Inc (OGEN) Institutional Confidence - TradingKey
Oragenics Inc (OGEN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Oragenics Inc (OGEN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Oragenics Inc (OGEN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Oragenics Inc (OGEN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Oragenics Inc (OGEN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Oragenics Inc (OGEN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
OGEN Q2 2023 Earnings: EPS Beat Despite No Revenue, Stock DeclinesEarnings Yield Spread - newsline.com
OGEN Q2 2023 Earnings: EPS Beat on Lower-than-Expected Loss, But Stock DeclinesEarnings Volatility Report - newsline.com
OGEN Q2 2023 Earnings: Loss Narrower Than Expected but No Revenue, Stock DeclinesQuarterly Earnings Report - newsline.com
OGEN Q2 2023 Earnings: Narrower Loss Drives 5% Bounce on Surprise BeatRevenue Growth Report - newsline.com
Oragenics Inc. (OGEN) Gains Ground: Potential Breakout Above $0.65 in Sight?Swing Trade Setups - newsline.com
OGEN Q2 2023 Earnings: Smaller-Than-Expected Loss as Clinical Pipeline ProgressesProduct Revenue Analysis - newsline.com
Oragenics Inc. (OGEN) Edges Lower to $0.60, Testing Key Support LevelsEarnings Quality Factor - newsline.com
OGEN Q2 2023 Earnings: EPS Beats Estimates by Over 50% as Company Advances PipelineBanking Earnings Report - newsline.com
OGEN News | ORAGENICS INC (NYSEARCA:OGEN) - ChartMill
ORAGENICS INC (OGEN) Stock Chart - ChartMill
OGEN Q2 2023 Earnings: Narrower-than-expected loss as EPS beats estimates by over 50%Annual Earnings Summary - dars.gov.et
Oragenics Inc. (OGEN) Inches Higher as Stock Tests Key Resistance Near $0.64SuperTrend Flip - newsline.com
Oragenics Inc. (OGEN) Slips Amid Low Volume, Hovers Near Key SupportIceberg Order - newsline.com
Oragenics Inc. (OGEN) Edges Higher as Biotech Volatility PersistsIceberg Order - The Legal Advocate
OGEN Q2 2023 Earnings: Narrower-than-Expected Loss Boosts Investor SentimentOpen Signal Network - Newser
OGEN | Oragenics Inc. Executive Compensation - Quiver Quantitative
Oragenics Q2 2023 Earnings: Narrowing Loss Surprises, No Revenue YetFull Year Guidance - Newser
Oragenics to Present at Sidoti's Micro-Cap Virtual Investor Conference May 20-21 - marketscreener.com
Oragenics (OGEN) Rallies +4.50% as Bulls Target $0.63 2026-05-20Community Buy Signals - Newser
Oragenics to Present at Sidoti Micro-Cap Virtual Investor Conference, Highlighting Progress on Concussion Treatment - MEXC
Oragenics Highlights Investor Outreach at Micro-Cap Conference - TipRanks
Oragenics to Present at Sidoti’s Micro-Cap Virtual Investor Conference May 20-21 - Yahoo Finance
Oragenics advances ONP-002 Phase IIa in Australia, $6.1M cash and LOI for CNS device - TradingView
ORAGENICS PROVIDES INVESTOR UPDATE - Sahm
Oragenics (OGEN) Q2 2023 Earnings Surprise: EPS $-1.51, Up SignificantBanking Earnings Report - Newser
Oragenics Advances Phase IIa Trial for Concussion Treatment, Eyes CNS Expansion - citybuzz -
Oragenics advances concussion drug trial, signs device LOI - Investing.com UK
Oragenics advances concussion drug trial, signs device LOI By Investing.com - Investing.com Nigeria
OGEN Technical Analysis | Trend, Signals & Chart Patterns | ORAGENICS INC (NYSEARCA:OGEN) - ChartMill
TradingKey - TradingKey
Oragenics (OGEN) continues pipeline investments amid losses; CEO discusses strategic priorities and funding outlook.Crowd Entry Points - Newser
Oragenics: Q1 Earnings Snapshot - 10tv.com
Oragenics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Oragenics | 10-Q: Q1 2026 Earnings Report - Moomoo
Oragenics Signs LOI to License CardioDialysis Technology for Neurodegenerative Diseases - citybuzz -
Oragenics signs letter of intent to license blood purification tech - Investing.com
Oragenics signs letter of intent to license blood purification tech By Investing.com - Investing.com Australia
Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation - ChartMill
Oragenics IncSigns Letter Of Intent To License Cardiodialysis From Sigyn TherapeuticsSEC Filing - TradingView
1.05%
0.85%
大文字化:
|
ボリューム (24 時間):